Stocks › ELV
Elevance Health, Inc. (ELV) stock analysis
WEAK BUY 19% confidence · analysed Nov 3, 2026
On Nov 3, 2026, our model rated Elevance Health, Inc. (ELV) WEAK BUY with 19% confidence at a price of $412.98. That means the signals lean positive, but they are mixed, so conviction is low.
Technical picture
The 14-day RSI is 40. Momentum is soft: below the neutral 50 line, but not yet oversold.
MACD is below its signal line, so short-term momentum is pointing down.
The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.
Volume is only 0.4x its 20-day average; light trading makes the latest move less convincing.
Trend structure and money flow
Market structure: bullish structure intact, no fresh break.
The most recent swing high is $434.35 and the swing low is $361.41; traders often treat these as resistance and support.
Fundamentals
The PEG ratio is 1.27, which looks reasonably priced for its growth.
The company reports a profit margin of 2.5% and revenue growth of +1.4%.
In its latest quarter it earned $6.99 per share, which beat the $4.69 analysts expected, with revenue +1.4% year over year.
Wall Street's average rating is 1.8 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $482.38.
The next earnings report is expected around Jan 28, 2027; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $413.07, a target of $429.99 (+4.1%) and a stop-loss at $389.07 (-5.8%).
That is a reward-to-risk ratio of about 0.7 to 1: the potential loss is bigger than the gain, a weak setup.
The plan has a time limit: reassess by Nov 13, 2026 whatever the price does.
The model's one-paragraph read
Leans BUY — composite score +0.19 (WEAK BUY). Technicals: RSI 40.21, MACD bearish, price above SMA50. Fundamentals: PEG 1.27, margin 2.5%, revenue growth 1.4%. Financial results: YoY revenue +1.4%, last EPS surprise +49.0%, next earnings 2027-01-28. Smart Money Concepts: bullish structure intact, no fresh break. FinGPT news read: positive. Suggested levels: entry $413.07, target $429.99, stop-loss $389.07, exit by 2026-11-13 (10-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for ELV
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Nov 3, 2026 | WEAK BUY | 19% | $412.98 | — |
"Move since" compares each call's price with the latest analysed price.
Frequently asked questions
Is ELV a buy right now?
As of Nov 3, 2026, our automated model rates Elevance Health, Inc. (ELV) WEAK BUY with 19% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for ELV?
The model's most recent plan targets $429.99 with a stop-loss at $389.07, from an entry near $413.07.
When does Elevance Health, Inc. report earnings next?
The next earnings report is expected around Jan 28, 2027.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.